BMS-986020 clinical trials
Also written BMS-986020.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses BMS-986020 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BMS-986020
- 4
Studies by the year they started
5 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BMS-986020 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisCompletedPhase 2Bristol-Myers SquibbNCT01766817Written as BMS-986020
- A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)WithdrawnPhase 2Bristol-Myers SquibbNCT02588625Written as BMS-986020
- A Phase 1 Drug-drug Interaction Study in Healthy VolunteersCompletedPhase 1Bristol-Myers SquibbNCT02227173Written as BMS-986020
- Drug Interaction Study With RosuvastatinCompletedPhase 1Bristol-Myers SquibbNCT02101125Written as BMS-986020
- Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020CompletedPhase 1Bristol-Myers SquibbNCT02068053Written as [14C] BMS-986020